Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases

Journal of Clinical Oncology

Volumn 21, Issue 10, 2003, Pages 1973-1979

  Bardou, Valerie Jeanne ^a   Arpino, Grazia ^a   Elledge, Richard M ^a   Osborne, C Kent ^a   Clark, Gary M ^a  

^a HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROGESTERONE RECEPTOR; ESTROGEN RECEPTOR;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER RISK; CANCER SURVIVAL; HORMONAL THERAPY; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; TUMOR VOLUME; ADULT; AGED; BREAST TUMOR; DISEASE FREE SURVIVAL; FEMALE; METABOLISM; MIDDLE AGED; MORTALITY; NEOPLASM; PATHOLOGY; REGISTER; STATISTICAL MODEL; SURVIVAL; TREATMENT OUTCOME; TUMOR RECURRENCE; UNITED STATES;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LOGISTIC MODELS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, HORMONE-DEPENDENT; PROGNOSIS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; REGISTRIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; UNITED STATES;

EID: 0038688478     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.09.099     Document Type: Article

References (27)

1. McGuire WL: Prognostic factors for recurrence and survival in human breast cancer. Breast Cancer Res Treat 10:5-9, 1987
2. Breast Cancer Trials Committee: Adjuvant tamoxifen in the management of operable breast cancer: The Scottish Trial-Report from the Breast Cancer Trials Committee, Scottish Cancer Trials Office (MRC), Edinburgh. Lancet 2:171-175, 1987
3. Fisher ER, Sass R, Fisher B, et al: Pathologic findings from the National Surgical Adjuvant Breast Project (protocol 6): II. Relation of local breast recurrence to multicentricity. Cancer 57:1717-1724, 1986
4. Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer: An overview of the randomised trials-Early Breast Cancer Trialists' Collaborative Group. Lancet 351:1451-1467, 1998
5. Horwitz KB, McGuire WL: Specific progesterone receptors in human breast cancer. Steroids 25:497-505, 1975
6. Elledge RM, Green S, Pugh R, et al: Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: A Southwest Oncology Group Study. Int J Cancer 89:111-117, 2000
7. Ravdin PM, Green S, Dorr TM, et al: Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: Results of a prospective Southwest Oncology Group study. J Clin Oncol 10:1284-1291, 1992
8. McGuire WL, De La Garza M, Chamness GC: Evaluation of estrogen receptor assays in human breast cancer tissue. Cancer Res 37:637-639, 1977
9. Powell B, Garola RE, Chamness GC, et al: Measurement of progesterone receptor in human breast cancer biopsies. Cancer Res 39:1678-1682, 1979
10. Dressler LG, Seamer LC, Owens MA, et al: DNA flow cytometry and prognostic factors in 1331 frozen breast cancer specimens. Cancer 61:420-427, 1988
11. Kaplan EL, Meier P: Non-parametric estimation for incomplete observation. J Am Stat Assoc 53:457-471, 1958
12. Peto R, Peto J: Asymptotically efficient rank invariant test procedures. J R Stat Soc A 135:185-207, 1972
13. Cox DR: Regression models and life table (with discussion). J R Stat Soc A 34:187-202, 1972
14. Aamdal S, Bormer O, Jorgensen O, et al: Estrogen receptors and long-term prognosis in breast cancer. Cancer 53:2525-2529, 1984
15. Hahnel R, Woodings T, Vivian AB: Prognostic value of estrogen receptors in primary breast cancer. Cancer 44:671-675, 1979
16. Hilsenbeck SG, Ravdin PM, de Moor CA, et al: Time-dependence of hazard ratios for prognostic factors in primary breast cancer. Breast Cancer Res Treat 52:227-237, 1998
17. Coradini D, Daidone MG, Boracchi P, et al: Time-dependent relevance of steroid receptors in breast cancer. J Clin Oncol 18:2702-2709, 2000
18. Ferno M, Stal O, Baldetorp B, et al: Results of two or five years of adjuvant tamoxifen correlated to steroid receptor and S-phase levels: South Sweden Breast Cancer Group, and South-East Sweden Breast Cancer Group. Breast Cancer Res Treat 59:69-76, 2000
19. Ellis MJ, Coop A, Singh B, et al: Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: Evidence from a phase III randomized trial. J Clin Oncol 19:3808-3816, 2001
20. Rutqvist LE, Cedermark B, Fornander T, et al: The relationship between hormone receptor content and the effect of adjuvant tamoxifen in operable breast cancer. J Clin Oncol 7:1474-1484, 1989
21. Arafah BM, Finegan HM, Roe J, et al: Hormone dependency in N-nitrosomethylurea-induced rat mammary tumors. Endocrinology 111:584-588, 1982
22. Horwitz KB, McGuire WL, Pearson OH, et al: Predicting response to endocrine therapy in human breast cancer. Science 189:726-727, 1975
23. McGuire WL: Breast cancer prognostic factors: Evaluation guidelines. J Natl Cancer Inst 83:154-155, 1991
24. Fuqua SA, Fitzgerald SD, Chamness GC, et al: Variant human breast tumor estrogen receptor with constitutive transcriptional activity. Cancer Res 51:105-109, 1991
25. Harvey JM, Clark GM, Osborne CK, et al: Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17:1474-1481, 1999
26. Allred DC, Harvey JM, Berardo M, et al: Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11:155-168, 1998
27. National Institutes of Health: NIH Consensus Development Conference on Adjuvant Therapy for Breast Cancer. Bethesda, MD, National Institutes of Health, 2000